TickerFactsScreenerDevelopers

Taysha Gene Therapies, Inc. (TSHA) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2020: -$30.73M2021: -$117.04M2022: -$88.39M2023: -$73.02M2024: -$81.22M2025: -$93.09M-$93.09M
2020Operating Cash Flow (USD)2025
Fiscal YearOperating Cash FlowChange YoY
2025-$93.09M-14.6%
2024-$81.22M-11.2%
2023-$73.02M+17.4%
2022-$88.39M+24.5%
2021-$117.04M-280.9%
2020-$30.73M—